Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.37 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.34 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234142 | 0.89 | ENPP2 (0.51) | PRKCALPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL234633 | 0.84 | SMN1; SMN2 (0.59) | PRKCASMN1; SMN2NR5A2NR5A1BLM | |
| SCHEMBL27219506 | 0.84 | SMN1; SMN2 (0.59) | PRKCASMN1; SMN2NR5A2NR5A1BLM | |
| SCHEMBL21686371 | 0.83 | PRKCA (0.50) | PRKCABLMALDH1A1LMNA | |
| SCHEMBL23761110 | 0.82 | FABP3 (0.43) | PRKCALPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL51010 | 0.82 | FABP3 (0.43) | PRKCALPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL29451071 | 0.82 | FABP3 (0.43) | PRKCALPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL26236288 | 0.82 | SELP (0.49) | PRKCALPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL20111594 | 0.82 | FABP3 (0.43) | PRKCALPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL480702 | 0.81 | PRKCA (0.63) | PRKCABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250237-A1 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-10-13 | — | — | US | disclosed |
| EP-2313085-A2 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | Novartis AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-20110064755-A1 | METHODS FOR PRODUCING BLOCK COPOLYMER/AMPHIPHILIC PARTICLES | VICAL INCORPORATED (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2010009277-A9 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | NOVARTIS AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010009277-A2 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20060134221-A1 | Methods for producing block copolymer/amphiphilic particles | VICAL INCORPORATED (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250237-A1 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | TAP1, TAP2, MICA | PRKCA 2094/4885LPAR3 1217/4885LPAR1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.